About Dimension
Dimension is a stage-agnostic investment firm that partners with founders operating at the edges of technology, machine learning (ML), and the life sciences. We believe the lines between these technologies are blurring. The developments that define this century will stem from physicists, biologists, chemists, and computationalists working hand-in-hand. To our future entrepreneurs, we cannot wait to build with you.
About Dimension Research
Research is one Dimension’s core pillars. Amongst other things, we are the firm’s thesis development engine. Writing helps to sharpen our ideas and allows us to meet exceptional thinkers, researchers, founders, and operators—like you.
Current Research Roster
Simon Barnett, Partner & Head of Research
Simon has a dual background in life sciences research and buy-side finance. He is responsible for building the human and digital systems powering Dimension’s research engine.
Prior to Dimension, Simon led a biotech public equity research team for a multi-billion-dollar asset manager in NYC. His primary research focus was on human genetics and how the associated technologies were rewriting diagnostics, therapeutics, synthetic biology, and more. Simon has been featured on CNBC, TD Ameritrade, Yahoo! Finance, Investors Business Daily, the Timmerman Report, and Genetic Engineering & Biotechnology News.
He previously held research positions in risk-assessment, computer vision, and clinical oncology. Simon is originally from central Texas and has a BS in Chemical & Biomolecular Engineering from Johns Hopkins.
Bauer LeSavage, PhD, Research Associate
Bauer is a bioengineer by training with research experience in stem cell biology, cancer biology, immunology, and materials science.
Prior to Dimension, Bauer was the first Scientist hired to the R&D team at ImmuneBridge, a platform cell therapy company focused on scaling allogeneic cell therapy manufacturing. Bauer received his BS in Biomedical Engineering from Boston University where he graduated summa cum laude and was a Goldwater Scholar. He then received his MS and PhD in Bioengineering from Stanford University where he was a Siebel Scholar and awarded multiple research fellowships.
His doctoral research focused on developing engineered in vitro models of the tumor microenvironment to study chemoresistance mechanisms in patient-derived organoids. His work has been published in top peer-reviewed journals including Nature Materials, Science Advances, and JCI.
Our team is always growing. If you’re inspired by our work and focus—please message one of us about an opportunity.
